Pleuroparenchymal fibroelastosis as a late complication of childhood cancer therapy: A case series Journal Article

  


Authors: Marathe, P. H.; Santibanez, V.; Meyers, P. A.; Padilla, M. L.; Friedman, D. N.
Article Title: Pleuroparenchymal fibroelastosis as a late complication of childhood cancer therapy: A case series
Abstract: Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial pneumonia with distinct clinicopathologic features. It has been associated with exposure to hematopoietic stem cell transplantation (HSCT) and classical alkylating agents. Here, we highlight PPFE as a late complication of childhood cancer therapy by describing the cases of four survivors of childhood cancer with a diagnosis of treatment-related PPFE. All patients received high-dose alkylating agents. PPFE should be considered in the differential diagnosis of restrictive lung disease in patients with history of exposure to alkylating agents or HSCT. Development of PPFE-specific, noninvasive diagnostic tools and disease-modifying therapies will clinically benefit these patients. © 2024 Wiley Periodicals LLC.
Keywords: adolescent; adult; child; clinical article; human tissue; preschool child; school child; child, preschool; antibiotic agent; young adult; hydroxyurea; prednisone; case report; cisplatin; doxorubicin; cytarabine; methotrexate; temozolomide; neoplasm; neoplasms; carboplatin; computer assisted tomography; etoposide; lung disease; differential diagnosis; oxygen therapy; exercise; alkylating agent; cyclophosphamide; melphalan; vincristine; hematopoietic stem cell transplantation; pathology; cancer therapy; carmustine; ifosfamide; acute lymphoblastic leukemia; childhood cancer; irinotecan; ewing sarcoma; salbutamol; neuroblastoma; antineoplastic agents, alkylating; survivorship; dactinomycin; asparaginase; daily life activity; interstitial lung disease; thorax radiography; graft survival; isotretinoin; drug therapy; lung function; alkylating agents; lung function test; lung fibrosis; pulmonary fibrosis; therapy; tioguanine; etiology; medical history; adverse event; complication; ipratropium bromide; forced vital capacity; wedge resection; childhood cancer survivor; antifibrotic agent; lung diseases, interstitial; fluticasone; pleuroparenchymal fibroelastosis; humans; prognosis; human; male; female; article; total lung capacity; six minute walk test; pulmonary late effects; tiotropium bromide
Journal Title: Pediatric Blood and Cancer
Volume: 71
Issue: 7
ISSN: 1545-5009
Publisher: Wiley Periodicals, Inc  
Date Published: 2024-07-01
Start Page: e31004
Language: English
DOI: 10.1002/pbc.31004
PUBMED: 38637875
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190985687&doi=10.1002%2fpbc.31004&partnerID=40&md5=0bdf7c41b9abf92cc2d7ff45d7701244
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Danielle Novetsky Friedman
    110 Friedman
  2. Paul Meyers
    311 Meyers
  3. Priya Hemant Marathe
    5 Marathe
Related MSK Work